John Taylor - President & CEO

John joined Spyryx as CEO in December 2013 with the goal of building the Company into a therapeutic development organization targeting severe lung diseases. This role relies heavily on his prior experience in business and corporate development for small pharmaceutical and biotechnology companies, including considerable focus on rare and orphan diseases.  In addition to Spyryx, John has provided leadership to several other biopharmaceutical start-ups, including JUNCTIONRx, a company he founded to pursue orphan drug development.  Previously, he spent almost four years as Vice President, Corporate Development at Synageva BioPharma (acquired by Alexion Pharmaceuticals), a biotechnology company focused on protein therapeutics for rare diseases, which he helped to take public via a reverse merger with Trimeris.  Prior to joining Synageva, John was the Vice President, Business Development for Javelin Pharmaceuticals, a clinical and commercial stage specialty pharmaceutical company developing treatments for acute pain.  Earlier in his career John held positions of increasing responsibility in licensing and business development, marketing, and sales with Eurand Pharma, Sarnoff Corporation, Amersham Pharmacia Biotech and BioWhittaker.  John received his Bachelors degree in Biological Sciences from Clemson University and his Masters degree in Technology Management from the Wharton School of Business at the University of Pennsylvania.